One-year treatment of morpholino antisense oligomer improves skeletal and cardiac muscle functions in dystrophic mdx mice

Molecular Therapy

Volumn 19, Issue 3, 2011, Pages 576-583

  Wu, Bo ^a   Xiao, Bin ^b,c   Cloer, Caryn ^a   Shaban, Mona ^a   Sali, Arpana ^d   Lu, Peijuan ^a   Li, Juan ^b   Nagaraju, Kanneboyina ^d   Xiao, Xiao ^b   Lu, Qi Long ^a  

^a Neuromuscular/ALS Center   (United States)

^b University of North Carolina   (United States)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CREATINE KINASE; DYSTROPHIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTISENSE THERAPY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EXON; GENE EXPRESSION; GENE MUTATION; HISTOPATHOLOGY; LONG TERM CARE; MOUSE; MUSCULAR DYSTROPHY; NONHUMAN; REPEATED DRUG DOSE;

ANIMALIA; MUS;

EID: 79952189079     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.288     Document Type: Article

References (29)

1. Hoffman, E P, Brown, RH Jr and Kunkel, LM (1987). Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51: 919-928.
2. Laing, NG (1993). Molecular and Cell Biology of Muscular Dystrophy. In: Partridge, TA (ed.). Chapman: London, pp. 37-77.
3. Monaco, AP, Bertelson, CJ, Liechti-Gallati, S, Moser, H and Kunkel, LM (1988). An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 2: 90-95.
4. Athanasopoulos, T, Graham, IR, Foster, H and Dickson, G (2004). Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD). Gene Ther 11 Suppl 1: S109-S121. (Pubitemid 39359455)
5. England, SB, Nicholson, LV, Johnson, MA, Forrest, SM, Love, DR, Zubrzycka-Gaarn, EE et al. (1990). Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature 343: 180-182.
6. Tang, Y, Cummins, J, Huard, J and Wang, B (2010). AAV-directed muscular dystrophy gene therapy. Expert Opin Biol Ther 10: 395-408.
7. Sherratt, TG, Vulliamy, T, Dubowitz, V, Sewry, CA and Strong, PN (1993). Exon skipping and translation in patients with frameshift deletions in the dystrophin gene. Am J Hum Genet 53: 1007-1015. (Pubitemid 23313764)
8. Dunckley, MG, Manoharan, M, Villiet, P, Eperon, IC and Dickson, G (1998). Modifcation of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides. Hum Mol Genet 7: 1083-1090. (Pubitemid 28306871)
9. Mann, CJ, Honeyman, K, Cheng, AJ, Ly, T, Lloyd, F, Fletcher, S et al. (2001). Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc Natl Acad Sci USA 98: 42-47. (Pubitemid 32095860)
10. Dickson, G, Hill, V and Graham, IR (2002). Screening for antisense modulation of dystrophin pre-mRNA splicing. Neuromuscul Disord 12 Suppl 1: S67-S70. (Pubitemid 36158775)
11. Aartsma-Rus, A, Bremmer-Bout, M, Janson, AA, den Dunnen, JT, van Ommen, GJ and van Deutekom, JC (2002). Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy. Neuromuscul Disord 12 Suppl 1: S71-S77. (Pubitemid 36158776)
12. Lu, QL, Mann, CJ, Lou, F, Bou-Gharios, G, Morris, GE, Xue, SA et al. (2003). Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat Med 9: 1009-1014. (Pubitemid 37021780)
13. Lu, QL, Rabinowitz, A, Chen, YC, Yokota, T, Yin, H, Alter, J et al. (2005). Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci USA 102: 198-203. (Pubitemid 40094452)
14. Alter, J, Lou, F, Rabinowitz, A, Yin, H, Rosenfeld, J, Wilton, SD et al. (2006). Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 12: 175-177. (Pubitemid 43214742)
15. Wu, B, Moulton, HM, Iversen, PL, Jiang, J, Li, J, Li, J et al. (2008). Effective rescue of dystrophin improves cardiac function in dystrophin-defcient mice by a modifed morpholino oligomer. Proc Natl Acad Sci USA 105: 14814-14819.
16. Wu, B, Li, Y, Morcos, PA, Doran, TJ, Lu, P and Lu, QL (2009). Octa-guanidine morpholino restores dystrophin expression in cardiac and skeletal muscles and ameliorates pathology in dystrophic mdx mice. Mol Ther 17: 864-871.
17. Wu, B, Lu, P, Benrashid, E, Malik, S, Ashar, J, Doran, TJ et al. (2010). Dose-dependent restoration of dystrophin expression in cardiac muscle of dystrophic mice by systemically delivered morpholino. Gene Ther 17: 132-140.
18. Yokota, T, Lu, QL, Partridge, T, Kobayashi, M, Nakamura, A, Takeda, S et al. (2009). Effcacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann Neurol 65: 667-676.
19. Kinali, M, Arechavala-Gomeza, V, Feng, L, Cirak, S, Hunt, D, Adkin, C et al. (2009). Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 8: 918-928.
20. Van Deutekom, JC, Janson, AA, Ginjaar, IB, Frankhuizen, WS, Aartsma-Rus, A, Bremmer-Bout, M et al. (2007). Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 357: 2677-2686. http://www.avibio.com/news- detail.php?newsId=0085.
21. Townsend, D, Yasuda, S, Li, S, Chamberlain, JS and Metzger, JM (2008). Emergent dilated cardiomyopathy caused by targeted repair of dystrophic skeletal muscle. Mol Ther 16: 832-835. (Pubitemid 351587091)
22. Foster, K, Foster, H and Dickson, JG (2006). Gene therapy progress and prospects: Duchenne muscular dystrophy. Gene Ther 13: 1677-1685. (Pubitemid 44849032)
23. Wagner, KR, Lechtzin, N and Judge, DP (2007). Current treatment of adult Duchenne muscular dystrophy. Biochim Biophys Acta 1772: 229-237. (Pubitemid 46123913)
24. Matsuda, R, Nishikawa, A and Tanaka, H (1995). Visualization of dystrophic muscle fbers in mdx mouse by vital staining with Evans blue: evidence of apoptosis in dystrophin-defcient muscle. J Biochem 118: 959-964.
25. Silver, MM, Banerjee, D and Hudson, AJ (1983). Segmental myofber necrosis in myotonic dystrophy - An immunoperoxidase study of immunoglobulins in skeletal muscle. Am J Pathol 112: 294-301. (Pubitemid 13006778)
26. Bostick, B, Yue, Y, Long, C and Duan, D (2008). Prevention of dystrophin-defcient cardiomyopathy in twenty-one-month-old carrier mice by mosaic dystrophin expression or complementary dystrophin/utrophin expression. Circ Res 102: 121-130.
27. Burger, AJ, Notarianni, MP and Aronson, D (2000). Safety and effcacy of an accelerated dobutamine stress echocardiography protocol in the evaluation of coronary artery disease. Am J Cardiol 86: 825-829.
28. Townsend, D, Blankinship, MJ, Allen, JM, Gregorevic, P, Chamberlain, JS and Metzger, JM (2007). Systemic administration of micro-dystrophin restores cardiac geometry and prevents dobutamine-induced cardiac pump failure. Mol Ther 15: 1086-1092. (Pubitemid 46813611)
29. Yasuda, S, Townsend, D, Michele, DE, Favre, EG, Day, SM and Metzger, JM (2005). Dystrophic heart failure blocked by membrane sealant poloxamer. Nature 436: 1025-1029. (Pubitemid 41191686)